iRGD manufacturers
- iRGD peptide
-
- $72.00 / 1mg
-
2026-03-13
- CAS:1392278-76-0
- Min. Order:
- Purity: 98.77%
- Supply Ability: 10g
- Irgd
-
- $0.00 / 1g
-
2025-04-02
- CAS:1392278-76-0
- Min. Order: 50g
- Purity: 99%
- Supply Ability: 100kg
- Opiorphin
-
- $0.00 / 1g
-
2025-04-02
- CAS:1392278-76-0
- Min. Order: 50g
- Purity: 99%
- Supply Ability: 100kg
|
| Product Name: | iRGD | | Synonyms: | iRGD;c(CRGDKGPDC);L-Cysteine, L-cysteinyl-L-arginylglycyl-L-α-aspartyl-L-lysylglycyl-L-prolyl-L-α-aspartyl-, cyclic (1→9)-disulfide;iRGD TFA;iRGD peptide TFA salt;inhibit,Inhibitor,iRGD peptide,Integrin;2,2'-((3S,6R,11R,14S,20S,23S,31aS)-11-amino-23-(4-aminobutyl)-6-carboxy-14-(3-guanidinopropyl)-1,4,12,15,18,21,24,27-octaoxooctacosahydro-1H-pyrrolo[2,1-j][1,2]dithia[5,8,11,14,17,20,23,26]octaazacyclononacosine-3,20-diyl)diacetic acid;iGRD peptide | | CAS: | 1392278-76-0 | | MF: | C35H57N13O14S2 | | MW: | 948.04 | | EINECS: | | | Product Categories: | | | Mol File: | 1392278-76-0.mol |  |
| density | 1.68±0.1 g/cm3(Predicted) | | storage temp. | -20°C, protect from light | | solubility | DMSO: Soluble: =10 mg/mlPBS (pH 7.2): Soluble: =10 mg/ml | | form | Solid | | pka | 2.92±0.70(Predicted) | | color | White to off-white | | Water Solubility | Water : ≥ 50 mg/mL (52.74 mM) | | Sequence | H-Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys-OH(Disulfide bridge: Cys1-Cys9) |
| Uses | iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. | | in vivo | iRGD inserted in the oncolytic adenovirus ICOVIR15K (ICOVIR15K-iRGD) enhances early adenovirus dissemination through the tumor mass and elevates the antitumor effect in mice[1]. iRGD (4 mmol/kg, i.v.) in combination with 5-FU significantly suppresses the tumor growth in nude mice bearing human gastric cancer cells[2]. | | References | [1] Puig-Saus C, et al. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy. Gene Ther. 2014 Aug;21(8):767-74. DOI:10.1038/gt.2014.52
[2] Zhang L, et al. Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells. Biomed Pharmacother. 2017 Sep;93:1136-1143. DOI:10.1016/j.biopha.2017.06.103
[3] LU LU. Mitochondrial Metabolism Targeted Nanoplatform for Efficient Triple-Negative Breast Cancer Combination Therapy[J]. Advanced Healthcare Materials, 2021, 10 20. DOI: 10.1002/adhm.202100978
[4] YAO Y, SAW P E, NIE Y, et al. Multifunctional sharp pH-responsive nanoparticles for targeted drug delivery and effective breast cancer therapy†[J]. Journal of Materials Chemistry B, 2018, 4: 576-585. DOI: 10.1039/c8tb02600a |
| | iRGD Preparation Products And Raw materials |
|